If enacted, the recently reintroduced Palliative Care and Hospice Education Training Act (PCHETA) could make a dent in the recruitment barriers that hospices keep hitting. But clinical education will need a much larger boost to ensure a sustainable workforce, according to many providers. The training issue is a serious impediment to hospice recruitment, as very […]
The U.S. Centers for Medicare & Medicaid Services (CMS) recently proposed a 2.7% pay increase for hospice care for Fiscal Year 2023. However, that amount may be a drop in the bucket as COVID-19 headwinds rage, inflation surges and employee wages climb. Beyond the rising costs, Medicare is phasing in the return of payment sequestration, […]
LHC Group (NASDAQ: LHCG) will acquire home health and hospice operations in 22 states from the joint venture between Brookdale Senior Living (NYSE: BKD) and hospital system HCA Healthcare (NYSE: HCA). Brookdale sold an 80% stake in its home health, hospice and outpatient therapy business to HCA earlier this year in a $400 million deal. […]
Amedisys, Inc. (NASDAQ: AMED) is seeing its hospice and home health growth rates tripling based on rising patient census and a robust acquisitions pipeline. Hospice remains at the core of the company’s M&A strategy; Amedisys expects to see activity pick up in the home health sector as well this year. Baton Rouge, La.-based Amedisys last […]
An upswing in occupancy in Brookdale Senior Living (NYSE: BKD) facilities could bode well for the company’s hospice and home health business, which will soon transition to hospital system HCA Healthcare following completion of a $400 million transaction. HCA will assume 80% ownership of the segment with Brookdale retaining a 20% stake. Senior living occupancy […]
Rising volume in its hospice business helped deflect the impact of COVID-19 headwinds on Brookdale Senior Living’s (NYSE: BKD) Health Care Services Segment in the second quarter, which saw a sharp decline in home health admissions. Home health admissions have been falling off industry-wide during the pandemic due to widespread limitations on elective procedures and […]
The Amedisys, Inc. (NASDAQ: AMED) hospice segment saw a drop in referrals and rising costs stemming from the COVID-19 pandemic during the first quarter of this year. Though the outbreak creates industry-wide uncertainty about the future, demographic tailwinds, de novo activity and acquisitions show promise for a strong recovery, including the company’s $235 million purchase […]
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
